ES2129386T3 - Vacuna contra la gripe. - Google Patents

Vacuna contra la gripe.

Info

Publication number
ES2129386T3
ES2129386T3 ES98201056T ES98201056T ES2129386T3 ES 2129386 T3 ES2129386 T3 ES 2129386T3 ES 98201056 T ES98201056 T ES 98201056T ES 98201056 T ES98201056 T ES 98201056T ES 2129386 T3 ES2129386 T3 ES 2129386T3
Authority
ES
Spain
Prior art keywords
flu
propaged
viruses
dna
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98201056T
Other languages
English (en)
Other versions
ES2129386T1 (es
Inventor
Scharrenburg Gustaaf J M Van
Rudi Brands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duphar International Research BV
Original Assignee
Duphar International Research BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8228174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2129386(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duphar International Research BV filed Critical Duphar International Research BV
Publication of ES2129386T1 publication Critical patent/ES2129386T1/es
Application granted granted Critical
Publication of ES2129386T3 publication Critical patent/ES2129386T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCION TRATA DE UNA VACUNA DE UN ANTIGENO DE SUPERFICIE DE LA GRIPE, QUE PUEDE OBTENERSE MEDIANTE LA PRODUCCION A PARTIR DE VIRUS DE LA GRIPE PROPAGADOS EN UN CULTIVO DE CELULAS ANIMALES, Y QUE PRESENTA UN CONTENIDO EN ADN DE LA CELULA HUESPED IGUAL O MENOR QUE 25 PG POR DOSIS. LA PRESENTE INVENCION TAMBIEN TRATA DE UN PROCEDIMIENTO PARA LA PREPARACION DE PROTEINAS DE UN ANTIGENO DE SUPERFICIE PROCEDENTES DE VIRUS DE LA GRIPE PROPAGADOS EN UN CULTIVO DE CELULAS ANIMALES, QUE INCLUYEN LAS SIGUIENTES ETAPAS: A. TRATAMIENTO DEL FLUIDO QUE CONTIENE LOS VIRUS COMPLETOS OBTENIDO A PARTIR DEL CULTIVO CELULAR, CON UNA ENZIMA DE DIGESTION DE ADN, Y B. ADICION DE UN DETERGENTE CATIONICO, SEGUIDO DEL AISLAMIENTO DE LAS PROTEINAS DEL ANTIGENO DE SUPERFICIE.
ES98201056T 1997-04-09 1998-04-02 Vacuna contra la gripe. Expired - Lifetime ES2129386T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97201007 1997-04-09

Publications (2)

Publication Number Publication Date
ES2129386T1 ES2129386T1 (es) 1999-06-16
ES2129386T3 true ES2129386T3 (es) 2001-01-01

Family

ID=8228174

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98201056T Expired - Lifetime ES2129386T3 (es) 1997-04-09 1998-04-02 Vacuna contra la gripe.

Country Status (32)

Country Link
US (1) US5948410A (es)
EP (1) EP0870508B1 (es)
JP (1) JP5258127B2 (es)
KR (1) KR100593235B1 (es)
CN (1) CN1138564C (es)
AR (1) AR011216A1 (es)
AT (1) ATE197406T1 (es)
AU (1) AU728939B2 (es)
BR (1) BR9801015A (es)
CA (1) CA2234208C (es)
CZ (1) CZ297492B6 (es)
DE (2) DE870508T1 (es)
DK (1) DK0870508T3 (es)
DZ (1) DZ2462A1 (es)
ES (1) ES2129386T3 (es)
GR (2) GR990300017T1 (es)
HK (1) HK1010833A1 (es)
HR (1) HRP980187B1 (es)
HU (1) HUP9800802A3 (es)
ID (1) ID20399A (es)
IL (1) IL123961A (es)
NO (1) NO323349B1 (es)
NZ (1) NZ330131A (es)
PL (1) PL187982B1 (es)
PT (1) PT870508E (es)
RU (1) RU2197264C2 (es)
SI (1) SI0870508T1 (es)
SK (1) SK282614B6 (es)
TR (1) TR199800613A1 (es)
TW (1) TW570803B (es)
UA (1) UA42089C2 (es)
ZA (1) ZA982915B (es)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU764368B2 (en) * 1999-09-24 2003-08-14 Smithkline Beecham Biologicals (Sa) Intranasal influenza virus vaccine
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
CN100415769C (zh) * 2002-02-07 2008-09-03 中国科学院过程工程研究所 寡聚或多聚亚基蛋白质分离纯化的方法
MXPA04010603A (es) 2002-04-30 2004-12-13 Oncolytics Biotech Inc Metodos mejorados de purificacion viral.
US20060110406A1 (en) * 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
KR101251902B1 (ko) * 2003-02-25 2013-04-08 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
US7270990B2 (en) * 2003-06-20 2007-09-18 Microbix Biosystems, Inc. Virus production
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8506967B2 (en) 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
US8992939B2 (en) 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
CA2559371C (en) 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
CA2890962A1 (en) 2004-09-09 2006-03-16 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Decreasing potential iatrogenic risks associated with influenza vaccines
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CA2586690A1 (en) 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics, Inc. Influenza vaccination
ES2526170T3 (es) * 2004-12-23 2015-01-07 Medimmune, Llc Línea celular MDCK no tumorigénica para propagar virus
NZ561823A (en) 2005-03-23 2010-04-30 Glaxosmithkline Biolog Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
US8574595B2 (en) * 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
NZ567817A (en) 2005-11-01 2012-01-12 Novartis Vaccines & Diagnostic Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
WO2007052061A2 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
DK2368572T3 (da) 2005-11-04 2020-05-25 Seqirus Uk Ltd Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur
CN102727885A (zh) 2005-11-04 2012-10-17 诺华疫苗和诊断有限公司 包含颗粒佐剂和免疫增强剂组合的流感疫苗
JP2009514839A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
EP2043682B1 (en) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Influenza vaccine
GB0614460D0 (en) * 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
MX2009002741A (es) 2006-09-15 2009-05-11 Medimmune Llc Lineas de celulas mdck que soportan el crecimiento viral para altos titulos y proceso de biorreactor que utiliza las mismas.
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
BRPI0808333B8 (pt) * 2007-03-05 2021-05-25 Om Pharma extrato bacteriano para doenças respiratórias e processo para sua preparação
WO2008112218A2 (en) 2007-03-12 2008-09-18 Antigen Express, Inc. Li-rnai involved li suppression in cancer immunotherapy
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
CA2692200A1 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
EP2772267B1 (en) * 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2889042A3 (en) 2008-03-18 2015-10-14 Novartis AG Improvements in preparation of influenza virus vaccine antigens
CA2738022A1 (en) 2008-09-24 2010-04-01 Medimmune, Llc Methods for cultivating cells, propagating and purifying viruses
CA2741961A1 (en) * 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
EP2942062A1 (en) 2009-02-10 2015-11-11 Novartis AG Influenza vaccine regimens for pandemic-associated strains
US20120093860A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
PL2396032T3 (pl) 2009-02-10 2017-05-31 Seqirus UK Limited Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
USH2284H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
EP2401384B1 (en) 2009-05-21 2012-10-03 Novartis AG Reverse genetics using non-endogenous pol i promoters
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CA2767392C (en) 2009-07-06 2017-03-14 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
AU2010277310B2 (en) 2009-07-31 2015-01-15 Seqirus UK Limited Reverse genetics systems
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
PL2491117T3 (pl) 2009-10-20 2014-05-30 Novartis Ag Udoskonalone sposoby odzyskiwania wirusa wykorzystujące odwrotną genetykę
US9109013B2 (en) 2009-10-26 2015-08-18 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN103025350A (zh) 2010-05-21 2013-04-03 诺华有限公司 流感病毒的重配方法
PL2575873T3 (pl) 2010-06-01 2016-06-30 Novartis Ag Zatężanie i liofilizacja antygenów szczepionkowych grypy
CA2801149A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens without lyophilization
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
CA2808965C (en) 2010-08-20 2020-01-07 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
CA2852857A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
ES2628301T3 (es) 2012-03-02 2017-08-02 Seqirus UK Limited Recombinación de virus de gripe
WO2013182498A1 (en) 2012-06-04 2013-12-12 Novartis Ag Improved safety testing
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
MX2015006927A (es) 2012-12-03 2016-02-05 Novartis Ag Redistribucion de virus de la influenza.
CN111334530A (zh) 2013-03-13 2020-06-26 诺华股份有限公司 乙型流感病毒重配
JP2016521282A (ja) 2013-05-10 2016-07-21 ノバルティス アーゲー インフルエンザワクチンにおけるナルコレプシーのリスクの回避
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
BR112015030582A2 (pt) 2013-06-06 2017-08-29 Novartis Ag Segmento de hemaglutinina da gripe quimérico e de neuraminidase quimérico, proteína de hemaglutinina quimérica, vírus da gripe rearranjado, métodos para preparação de um vírus da gripe rearranjado e para preparação de uma vacina e sistema de expressão
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
RU2535153C1 (ru) * 2013-09-04 2014-12-10 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства России (ФГУП СПбНИИВС ФМБА России) Способ получения высокоочищенных вирионных концентратов
ES2817928T3 (es) 2013-11-15 2021-04-08 Novartis Ag Eliminación de impurezas de cultivos celulares residuales
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
EP2966093A1 (en) 2014-07-07 2016-01-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Process for the preparation of magnetic sulfated cellulose particles, magnetic sulfated cellulose particles and their use
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
RU2614127C2 (ru) * 2015-06-04 2017-03-22 Общество с ограниченной ответственностью "НТфарма" Способ получения концентрата рекомбинантных псевдоаденовирусных частиц, экспрессирующих ген гемагглютинина вируса гриппа A/California/07/2009(H1N1)
JP2018524323A (ja) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド 抗原がマッチしたインフルエンザワクチン
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
US10416171B2 (en) 2015-07-07 2019-09-17 Seqirus UK Limited Influenza potency assays
CN109477074B (zh) 2016-02-19 2023-01-24 威斯康星旧生研究基金会 用于疫苗开发的改进的乙型流感病毒复制
EP3601543A4 (en) 2017-03-30 2021-01-27 Merck Sharp & Dohme Corp. ADDING NUCLEASES DIRECTLY TO CELL CULTURE TO FACILITATE DIGESTION AND RELEASE OF HOST CELL NUCLEIC ACIDS
RU2670001C1 (ru) * 2017-12-25 2018-10-17 Федеральное государственное бюджетное учреждение науки Институт биохимии и физиологии растений и микроорганизмов Российской академии наук Способ получения белков клеточной поверхности
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
CA3094174A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
CA3094173A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
MX2022006005A (es) 2019-11-18 2022-10-27 Seqirus Pty Ltd Metodo para producir virus de la influenza reagrupados.
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (es) * 1974-01-14 1977-07-15 Sandoz Ag
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
US4317811A (en) * 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
DE3237313A1 (de) * 1982-10-08 1984-04-12 Werner Heese Verfahren zur gewinnung und reinigung antigenhaltiger loesungen, insbesondere fuer influenza-viren, aus antigenhaltiger allantoisfluessigkeit
US4783411A (en) * 1984-10-22 1988-11-08 Janis Gabliks Influenza-A virus vaccine from fish cell cultures
US5173418A (en) * 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US5006472A (en) * 1988-06-03 1991-04-09 Miles Inc. Enzymatic purification process
WO1990010058A2 (en) * 1989-02-07 1990-09-07 Bio-Technology General Corp. Method for production and purification of hepatitis b vaccine
EP0389925B1 (en) * 1989-03-29 1995-12-27 The Research Foundation Of State University Of New York A method for purifying an outer membrane protein of Haemophilus influenzae
DZ1706A1 (fr) * 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
HRP950097A2 (en) * 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
ATE429246T1 (de) * 1994-11-10 2009-05-15 Baxter Healthcare Sa Verfahren zur herstellung von biologischen produkten in protein-freiem kultur
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
KR19990036028A (ko) * 1995-08-01 1999-05-25 다니엘 케르니 일본뇌염 백신의 공업적인 생산방법 및 이에 의한 백신
KR19990063672A (ko) * 1995-09-28 1999-07-26 유니버시티 오브 피츠버그 오브 더 코몬웰츠 시스템 오브 하이어 에듀케이션 표적배향된 미립자물 유전 면역화에 의한 세포-매개 면역응답의 자극.

Also Published As

Publication number Publication date
HU9800802D0 (en) 1998-05-28
HK1010833A1 (en) 1999-07-02
DE870508T1 (de) 1999-08-19
CZ105098A3 (cs) 1998-10-14
CN1138564C (zh) 2004-02-18
DE69800383D1 (de) 2000-12-14
EP0870508A1 (en) 1998-10-14
AU728939B2 (en) 2001-01-18
MX9802766A (es) 1998-12-31
ID20399A (id) 1998-12-10
NO323349B1 (no) 2007-04-02
DK0870508T3 (da) 2000-11-20
PT870508E (pt) 2001-04-30
CN1196956A (zh) 1998-10-28
AU6065998A (en) 1998-10-15
PL325722A1 (en) 1998-10-12
RU2197264C2 (ru) 2003-01-27
ES2129386T1 (es) 1999-06-16
JP5258127B2 (ja) 2013-08-07
US5948410A (en) 1999-09-07
ATE197406T1 (de) 2000-11-11
GR990300017T1 (en) 1999-06-30
GR3034798T3 (en) 2001-02-28
AR011216A1 (es) 2000-08-02
IL123961A (en) 2000-07-16
NO981557D0 (no) 1998-04-06
NO981557L (no) 1998-10-12
HUP9800802A3 (en) 2003-08-28
HRP980187B1 (en) 2001-04-30
HRP980187A2 (en) 1999-04-30
TW570803B (en) 2004-01-11
EP0870508B1 (en) 2000-11-08
DZ2462A1 (fr) 2003-01-18
CA2234208C (en) 2003-06-10
UA42089C2 (uk) 2001-10-15
KR19980081114A (ko) 1998-11-25
ZA982915B (en) 1999-01-21
SK282614B6 (sk) 2002-10-08
SK44598A3 (en) 1998-11-04
DE69800383T2 (de) 2001-08-16
TR199800613A1 (xx) 1998-10-21
BR9801015A (pt) 2000-01-11
PL187982B1 (pl) 2004-11-30
KR100593235B1 (ko) 2007-12-04
HUP9800802A2 (hu) 1999-04-28
NZ330131A (en) 1999-10-28
JPH1121253A (ja) 1999-01-26
CA2234208A1 (en) 1998-10-09
SI0870508T1 (en) 2001-02-28
CZ297492B6 (cs) 2007-01-03

Similar Documents

Publication Publication Date Title
ES2129386T3 (es) Vacuna contra la gripe.
AU2006234304B2 (en) Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines
AR042378A2 (es) Poxvirus recombinante de mapache, vacuna para uso en gatos y uso de dicho poxvirus para preparar una vacuna eficaz contra la infeccion del virus de inmunodeficiencia felina
Harpin et al. Vaccination of cattle with a DNA plasmid encoding the bovine viral diarrhoea virus major glycoprotein E2
Cagle et al. Differences in pathogenicity, response to vaccination, and innate immune responses in different types of ducks infected with a virulent H5N1 highly pathogenic avian influenza virus from Vietnam
Kilbourne et al. Influenza Virus Polypeptides and Antigens: Summary of Influeza Workshop I
CY1115749T1 (el) Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
AR071220A1 (es) Astrovirus aviario depositado bajo el nuero cncm i-3895
UY27365A1 (es) Vacuna de mycoplasma bovis y métodos para reducir la neumonía en animales
ES2062887T3 (es) Secuencias de adn derivadas del genoma del papilomavirus hpv39, su aplicacion al diagnostico in vitro y a la produccion de preparado inmunogeno.
NO883594L (no) Fremgangsmaate for fremstilling av preparater av dobbeltraadet rna.
CA2331368A1 (en) Nucleic acid vaccines for prevention of flavivirus infection
Bi et al. Induction of a robust immunity response against novel duck reovirus in ducklings using a subunit vaccine of sigma C protein
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
FR2600079B1 (fr) Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
ATE295884T1 (de) Dna-expressionskonstrukt zur behandlung von infektionen mit leishmaniose
AU2018200081B2 (en) Avirulent, immunogenic flavivirus chimeras
ATE332920T1 (de) Nukleinsäureimpfstoff bestehend aus einem fusionsprotein, dass eine adjuvanssequenz von einem planzenvirushüllprotein aufweist
BR0110791A (pt) Composição, métodos para induzir uma resposta imune em um indivìduo contra um imunogene, para modular o sistema imune de um indivìduo e para imunizar um indivìduo contra um patógeno, vacina recombinante, e patógeno atenuado vivo
ATE84722T1 (de) Tollwut-lebendimpfstoff.
KAWAKITA et al. The action of immune serum on the Japanese encephalitis virus cultivated in vitro

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 870508

Country of ref document: ES